Opinion|Videos|October 18, 2024
Use of Long-term NMOSD Data in Clinical Practice
Author(s)Sean Pittock, MD
Key Takeaways
- Long-term data aids in optimizing treatment plans by offering insights into efficacy, safety, and patient outcomes over time.
- Staying updated with research findings is essential for integrating long-term data into clinical practice to enhance patient care.
Sean Pittock, MD, discusses how he utilizes long-term data in his clinical practice for treating neuromyelitis optica spectrum disorder and offers advice for physicians on incorporating these insights into patient care.
Advertisement
Episodes in this series
Video content above is prompted by the following:
How are you utilizing these long-term data in your clinical practice, and what advice do you have for physicians?
Advertisement
Related to this article
The FDA extended its review of relutrigine for SCN2A- and SCN8A-related epilepsies by three months, pushing the PDUFA date to December 27, 2026.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is clinical trial results in Alzheimer disease!
In recognition of International Ataxia Awareness Day, observed annually on September 25, NeurologyLive® reviews 6 investigational agents in clinical development across ataxia-related disorders.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
A. Blake Buletko, MD, and Galina Gheihman, MD, discuss their career paths in neurology, the role of mentorship and resilience, and strategies for navigating professional growth as early-career clinician-educators.
One-year KYSA-6 data showed KYV-101, a CD19 CAR T-cell therapy, produced durable, drug-free responses in generalized myasthenia gravis.
Final 15-month phase 1/2 data showed SKY-0515 improved cUHDRS scores and lowered mutant huntingtin protein in early-stage Huntington disease.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Azetukalner NDA Submitted, EMA Gives Approval Recommendation to Ocrelizumab, Phase 3 FUSION Trial Meets End Points
2
FDA Extends Relutrigine Review, Delays PDUFA to December
3
What's Next in Ataxia: Pipeline Overview of Investigational Therapeutics
4
SKY-0515 Shows Sustained Benefit at 15 Months in Huntington Disease
5